Up To 50 SAR OFF Your First Order Use Code : APP50 | Get Free Delivery With No Minimum Order

Frequently bought together
DIPROSONE 0.05% OINT 30G
- Sku : I-001695
Key features
DIPROSONE OINTMENT is a prescription topical ointment containing 0.05% betamethasone dipropionate. It is a potent topical corticosteroid that reduces inflammation and itching by activating glucocorticoid receptors in the skin, suppressing inflammatory mediators and producing local vasoconstriction. It is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid‑responsive dermatoses such as eczema/atopic dermatitis and psoriasis. Supplied as a 30 g ointment tube for prescription use.- Brand: DIPROSONE
- Active Ingredient: BETAMETHASONE DIPROPIONATE
- Strength: 0.05%
- Dosage Form: Ointment
- Pack Size: 30 g
- Route: Topical
- Prescription Status: Prescription
- Therapeutic Class: Dermatological
- Pharmacological Group: Corticosteroids (Plain)
- Manufacturer: Organon Heist bv
- Country of Origin: Belgium
- SFDA Registration No.: 0905233617
- Shelf Life: 36 months
- Storage: store below 30°c
- Skin Condition: Eczema, Psoriasis, Contact Dermatitis, Atopic Dermatitis
- Steroid Potency: Potent.
Frequently bought together
Indications
Approved Uses
Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., eczema/atopic dermatitis and psoriasis).
Dosage & Administration
Dosing by Condition
For corticosteroid-responsive dermatoses (including eczema/dermatitis and psoriasis): apply a thin layer to affected areas once or twice daily; reassess if not improving within ~2 weeks and avoid prolonged continuous use without clinician review.
Dose Adjustment Notes
Use the minimum effective amount for the shortest duration; apply once or twice daily and reduce frequency/stop as control is achieved; avoid use on large areas, under occlusion, or in skin folds unless directed due to increased systemic absorption; prolonged continuous use should generally not exceed 2-4 weeks without reassessment.
How to Take
For topical use only: wash and dry hands, apply a thin layer to the affected skin and rub in gently; avoid eyes, mouth, and mucous membranes and do not apply to broken/infected skin unless directed; wash hands after application (unless treating hands); do not use occlusive dressings/bandages unless prescribed.
Side Effects
Side Effect Frequency
Common: local burning/stinging, pruritus, irritation, dryness; Uncommon/Rare: folliculitis, acneiform eruptions, hypopigmentation, hypertrichosis, allergic contact dermatitis, perioral dermatitis, secondary infection, maceration, miliaria; Skin atrophy/striae and HPA-axis suppression are uncommon overall but risk increases with prolonged use, occlusion, large areas, and use on thin skin/children.
Safety & Warnings
Contraindications
Hypersensitivity to betamethasone dipropionate/excipients; untreated cutaneous viral infections (e.g., herpes simplex, varicella/vaccinia); untreated fungal or bacterial skin infections; rosacea; acne vulgaris; perioral dermatitis; pruritus ani/genital pruritus; not for ophthalmic use (avoid ocular application).
Drug Interactions
Drug Interactions
Clinically significant interactions are uncommon, but additive systemic corticosteroid effects can occur with other corticosteroids; strong CYP3A4 inhibitors (e.g., ritonavir/cobicistat, itraconazole) may increase systemic steroid effects if absorption is significant (large area, prolonged use, occlusion).
Interaction Severity
MODERATE: Strong CYP3A4 inhibitors (e.g., ritonavir/cobicistat, itraconazole) may increase systemic corticosteroid effects if significant percutaneous absorption occurs (large area, prolonged use, occlusion, pediatrics). MINOR: Concomitant use with other corticosteroids (topical/systemic) can add to total steroid burden.
Special Populations
Pregnancy
Caution
Breastfeeding
Caution
Storage & Patient Advice
Stopping the Medicine
Do not stop abruptly after prolonged use or use on large areas/under occlusion; taper by reducing frequency/potency to avoid rebound dermatitis and potential adrenal suppression.
Overdose
Excessive/prolonged topical use can cause HPA-axis suppression and hypercortisolism (Cushingoid features), hyperglycemia/glucosuria; manage by gradual withdrawal, supportive care, and monitoring adrenal function; accidental ingestion warrants medical assessment and symptomatic management.
Product Information
Available Dosage Forms
Ointment
Generic Availability
Yes
Skin Condition
Eczema, Psoriasis, Contact Dermatitis, Atopic Dermatitis
Steroid Potency
Potent.
Legal Disclaimer - Al Mujtama Pharmacy
The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.
Al Mujtama Pharmacy assumes no legal or medical liability for:
- Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
- Any discrepancy between the information provided and the product's package insert or SFDA guidelines
- Any misuse of medication resulting from personal interpretation of the content displayed
Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.
By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.
Your health is a trust - always consult your doctor first.
-1744229570.gif)













